Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in High-Risk MDS
NCT00906334Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- May 2009
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by Traws Pharma, Inc.. Started May 2009; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00906334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00906334.